医学
急性肾损伤
重症监护医学
中止
观察研究
肌酐
肾病科
立场声明
病因学
尿量
重症监护室
临床试验
肾脏疾病
内科学
复苏
梅德林
肾功能
灵丹妙药
多学科方法
泌尿系统
职位(财务)
高钾血症
指南
重症监护
随机对照试验
决策支持系统
来复枪
临床决策支持系统
临床判断
人工肾
临床决策
经济短缺
急诊医学
肾
作者
Fabiano Bichuette Custódio,José Hermógenes Rocco Suassuna,Lúcia Andrade,Luís Yu,Maurício Younes-Ibrahim,Eduardo Rocha,Ciro Bruno Silveira Costa,Pedro Túlio Rocha,José A. Moura-Neto,Daniela Ponce
标识
DOI:10.1590/2175-8239-jbn-2026-0026en
摘要
ABSTRACT Acute kidney injury (AKI) affects approximately 50% of patients admitted to the intensive care unit (ICU). Artificial renal support (ARS) is fundamental in the management of severe AKI. However, the decision regarding when to initiate and discontinue treatment remains a challenge. The debate over “early” initiation (based on biomarkers, creatinine elevation, or reduced urine output) versus “delayed” initiation (based on classic dialytic urgencies) continues to generate controversy. Recent clinical trials have attempted to elucidate which strategy confers the greatest benefit. Currently, the trend favors an individualized approach, integrating the etiology and trajectory of AKI, the patient’s clinical status, and the response to conservative therapy. The decision should be made in conjunction with a multidisciplinary team, carefully weighing risks and benefits. The discontinuation of ARS occurs when there is significant recovery of renal function. The criteria for interrupting ARS are less studied and are mostly derived from observational studies. The primary predictors of successful weaning include urine output (> 400 mL/day without diuretics, or > 2,000 mL/day with diuretics), creatinine clearance (> 15 mL/min), and the absence of electrolyte and acid-base disturbances. The Brazilian Society of Nephrology, through its AKI Department, recommends that the decision to initiate and discontinue ARS in AKI should be a dynamic process. It requires continuous patient assessment and must be personalized, based on both clinical and laboratory criteria. Advances in research—especially in artificial intelligence—and the development of new biomarkers may, in the future, provide more precise tools to guide these decisions and optimize AKI management.
科研通智能强力驱动
Strongly Powered by AbleSci AI